Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:08:27.445Z.
Calculation as of: 2026-10-06T17:08:27.445Z.
Quote observation: 2026-10-06T17:04:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 673a23962afa1f964289f2c5c8e96f6ae4ccf5481b64718d91ae2e5553a82c87
PEG RATIO
N/A
ProQR Therapeutics N.V.
Market Cap
$173.00M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| ProQR Therapeutics N.V. (PRQR) | $173.00M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $172.23M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $172.38M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.31M | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $171.07M | N/A |
| Journey Medical Corporation (DERM)vs › | $175.86M | N/A |
| MediWound Ltd. (MDWD)vs › | $169.76M | N/A |
| Nkarta, Inc. (NKTX)vs › | $169.20M | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $178.36M | N/A |
| OptimizeRx Corp. (OPRX)vs › | $166.08M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
